Funder: METAvivor
Due Dates (Anticipated): March 2026 (Letter of Intent) | August 2026 (Invited full application) | August 2026 (Internal submission)
Funding Amounts: Up to $200,000 total over 2 years; max $100,000/year including direct costs, up to $3,000 for travel, and 5% indirect costs.
Summary: Supports mechanism-based translational and clinical research to improve quality of life and mitigate side effects for people living with metastatic (stage IV) breast cancer.
Key Information: Patient advocate involvement is required throughout the project and application process.